Literature DB >> 1432159

Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.

U Haberkorn1, M Reinhardt, L G Strauss, F Oberdorfer, M R Berger, A Altmann, R Wallich, A Dimitrakopoulou, G van Kaick.   

Abstract

In order to quantify effects of an experimental chemotherapy, MCF7 cells were studied with 14C-fluorodeoxyglucose (FDG) and high-performance liquid chromatography (HPLC). Uptake measurements were performed 1 and 4 hr after the end of a therapy with hexadecylphosphocholine (HPC). A dose- and time-dependent increase of the FDG uptake after therapy was observed, with a maximum at 1 hr after therapy. These data were used to develop a new metabolic design of combination treatment. Several time-dose combinations of HPC and deoxyglucose (DOG) were analyzed for their effects on growth inhibition. The combinations using DOG in the period of pronounced enhancement of FDG uptake (1 hr after HPC treatment) were found to be the most effective with an improvement of up to 520% in growth inhibition. This metabolic design of combination treatment may also be applied in vivo, and PET can be used to optimize the time and dose schedule of the modified treatment protocol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432159

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

Review 1.  FDG-PET in monitoring therapy of breast cancer.

Authors:  H-J Biersack; H Bender; H Palmedo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-27       Impact factor: 9.236

2.  Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line.

Authors:  H Schaider; U Haberkorn; M R Berger; F Oberdorfer; I Morr; G van Kaick
Journal:  Eur J Nucl Med       Date:  1996-01

Review 3.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.

Authors:  L G Strauss
Journal:  Eur J Nucl Med       Date:  1996-10

4.  Changes in cervical cancer FDG uptake during chemoradiation and association with response.

Authors:  Elizabeth A Kidd; Maria Thomas; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-18       Impact factor: 7.038

5.  Combination treatment based on metabolic effects of dinaline.

Authors:  H Schaider; U Haberkorn; E Petru; M R Berger
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.

Authors:  Sebastian A Müller; Korbinian Holzapfel; Christof Seidl; Uwe Treiber; Bernd J Krause; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

7.  Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma.

Authors:  Uwe Haberkorn; Johannes Hoffend; Kerstin Schmidt; Annette Altmann; Gabriel A Bonaterra; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Michael Eisenhut; Ralf Kinscherf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-15       Impact factor: 9.236

8.  Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.

Authors:  Lei-qing Li; Fang Shen; Xiao-yan Xu; Hong Zhang; Xiao-feng Yang; Wei-guo Liu
Journal:  ScientificWorldJournal       Date:  2013-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.